Author: SIAIS
Time: 18 December 2016
An invited review article entitled “Advances in therapeutic Fc engineering - modulation of IgG associated effector functions and serum half-life” has recently been published in Frontiers in Immunology journal. This review article has been contributed by Dr. Abhishek Saxena as the first author (Senior Postdoctoral Fellow; Laboratory of Antibody Engineering, SIAIS) and Research Associate Prof. Donghui Wu as the correspondence author (Co-PI; Laboratory of Antibody Engineering, SIAIS). In this article, the authors summarize the recent advances in Fc linked effector functions including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP) and serum half-life for cancer treatment. The authors also discuss the progress made in aglycosylated mAb development that may substantially reduce the cost of manufacture but maintain similar efficacies as conventional glycosylated mAb. Finally, the authors highlight several Fc engineering-based mAbs under clinical trials.
Structural representation of key residues involved in Fc-FcγRs/FcRn interactions
Saxena A and Wu D (2016) Advances in Therapeutic Fc Engineering � Modulation of IgG-Associated Effector Functions and Serum Half-life. Front. Immunol. 7:580. doi: 10.3389/fimmu.2016.00580
http://journal.frontiersin.org/article/10.3389/fimmu.2016.00580/full
